Just two weeks after pleading guilty in a major federal fraud case, Amgen, the world’s largest biotechnology firm, scored a largely unnoticed coup on Capitol Hill: Congressional staff inserted a paragraph into the “fiscal cliff” bill in Section 632 of the law delays a set of Medicare price restraints on a class of drugs that includes Sensipar, that is projected to cost Medicare up to $500 million over the 2 year period.
http://www.nytimes.com/2013/01/20/us...anted=all&_r=0
If you think you've heard the name Amgen before around a settlement, you have....
Amgen to Pay $780 Million to Settle Suits on Its Sales
October 24, 2011
Amgen said Monday that it had set aside $780 million to settle various federal and state investigations and whistle-blower lawsuits accusing it of illegal sales and marketing tactics.
Amgen said it had reached an agreement in principle to settle criminal and civil investigations that had been under way for several years by the United States attorney offices in Brooklyn and Seattle.
http://www.nytimes.com/2011/10/25/health/25amgen.html
I will be surprised if this gets any notice here (or elsewhere). It's not as exciting as lip-syncing.